NASDAQ$CARM
Carisma Therapeutics Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Carisma Therapeutics reported financial results for the first quarter ended March 31, 2023 and provided business highlights.
Carisma Therapeutics closed its merger with Sesen Bio and is focused on advancing its pipeline, with multiple potential value inflection points on the horizon, including the completion of the Phase 1 clinical trial of CT-0508 and upcoming data from the clinical trial sub-study of CT-0508 in combination with KEYTRUDA®.
- Initiated a Phase 1 Sub-Study of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors.
- Expanded clinical manufacturing capacity through successful technology transfer of CT-0508.
- Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol “CARM”.
- Cash, cash equivalents and marketable securities of $139.0 million as of March 31, 2023 are sufficient to sustain planned operations through the end of 2024.
Headline financials
Revenue & EPS history
Carisma Therapeutics · Revenue · Quarterly
$3.24M
Revenue by segment
Carisma Therapeutics · $19.6M total across 1 segment · Q4 2024
- Collaboration Revenues$19.6M—100.0%
Forward guidance
Carisma believes that its cash, cash equivalents and marketable securities of $139.0 million as of March 31, 2023 are sufficient to sustain Carisma’s planned operations through the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2023
+0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+6.2%
Avg return
30 days after
54%
26 / 48 earnings
Positive
+32.8%
Q2 2016
Best reaction
-29.2%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +6.2% | +10.1% | -98.0% | |
| Q3 2025 | +2.4% | +27.8% | +22.6% | |
| Q2 2025 | -11.8% | -8.6% | +31.7% | |
| Q1 2025 | +3.1% | -1.4% | +153.1% | |
| Q4 2024 | +11.5% | +5.7% | -5.6% | |
| Q3 2024 | -9.0% | -10.4% | -28.0% | |
| Q2 2024 | +10.7% | +26.2% | +25.0% | |
| Q1 2024 | -4.5% | -5.8% | -30.3% | |
| Q4 2023 | -11.5% | -19.8% | -28.2% | |
| Q3 2023 | -19.5% | -11.1% | -15.4% | |
| Q2 2023 | +12.9% | +22.4% | -12.9% | |
| Q1 2023 | -12.3% | -17.7% | +4.1% | |
| Q4 2022 | +1.2% | -9.6% | +62.9% | |
| Q3 2022 | +0.5% | — | — | |
| Q2 2022 | -3.6% | — | — | |
| Q1 2022 | -1.3% | — | — | |
| Q4 2021 | -2.5% | — | — | |
| Q3 2021 | +3.4% | — | — | |
| Q2 2021 | -8.8% | — | — | |
| Q1 2021 | +5.4% | — | — | |
| Q4 2020 | +5.6% | — | — | |
| Q3 2020 | +3.9% | — | — | |
| Q2 2020 | +7.0% | — | — | |
| Q1 2020 | +1.6% | — | — | |
| Q4 2019 | -29.2% | — | — | |
| Q3 2019 | +0.9% | — | — | |
| Q2 2019 | +1.7% | — | — | |
| Q1 2019 | -2.9% | — | — | |
| Q4 2018 | +0.0% | — | — | |
| Q3 2018 | -7.0% | — | — | |
| Q2 2018 | +2.1% | — | — | |
| Q1 2018 | +17.1% | — | — | |
| Q4 2017 | +19.0% | — | — | |
| Q3 2017 | +2.8% | — | — | |
| Q2 2017 | -12.4% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +13.7% | — | — | |
| Q3 2016 | -4.2% | — | — | |
| Q2 2016 | +32.8% | — | — | |
| Q1 2016 | +6.1% | — | — | |
| Q4 2015 | -8.6% | — | — | |
| Q3 2015 | -0.7% | — | — | |
| Q2 2015 | +15.2% | — | — | |
| Q1 2015 | +17.9% | — | — | |
| Q4 2014 | -2.4% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -3.9% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro